Clinical Scenario

This protocol applies to patients with minimal change disease (MCD) who have entered a frequently relapsing or steroid-dependent course — where high-dose glucocorticoids were required to achieve initial remission but sustained, independent remission has not been maintained.

Previous Treatment — Failure Condition

First-line treatment consisted of high-dose oral glucocorticoids (Prednisolone), targeting complete remission with a decrease in proteinuria — an outcome the majority of patients reach within 8 weeks. When the clinical course becomes frequently relapsing or steroid-dependent rather than durably remitting, the goals of that initial line have not been met and escalation to the next step is indicated.

Next-Line Approach

Once remission is re-established, a steroid-sparing immunosuppressive strategy is introduced. Several agents from distinct pharmacological classes have demonstrated efficacy in this specific setting; the full structured regimen — agent selection, dosing, and duration — is available in the complete protocol.

References

DOI: 10.1016/j.kint.2021.05.021

We recommend cyclophosphamide, rituximab, CNIs, or mycophenolic acid analogs (MPAA) for the treatment of frequently relapsing/steroid-dependent MCD, rather than prednisone alone or no treatment (1C)
The randomised trial included 11 adults with FR or SD MCD, who received oral Cyclophosphamide (2.5mg/kg per day) for 8 weeks or Cyclosporine (5mg/kg per day) for 9 months then tapered by 12 months.
If a CNI based regime is used either Cyclosporine 3-5mg/kg/day in two divided doses or Tacrolimus 0.05-0.1mg/kg/day in two divided doses are suggested.
If MMF is used, 1g twice daily is suggested.

View source ↗

Frequently Relapsing or Steroid-Dependent Minimal Change Disease After Initial Glucocorticoid Therapy Has Failed

References